Carboplatin and Paclitaxel (Taxol) (8 cycles) versus Carboplatin and Paclitaxel (Taxol) (4 cycles) followed by Carboplatin (4 cycles) for frontline chemotherapy in advanced ovarian carcinoma. A randomised phase III study of overall survival by the Hellenic Cooperative Oncology Group

Trial Profile

Carboplatin and Paclitaxel (Taxol) (8 cycles) versus Carboplatin and Paclitaxel (Taxol) (4 cycles) followed by Carboplatin (4 cycles) for frontline chemotherapy in advanced ovarian carcinoma. A randomised phase III study of overall survival by the Hellenic Cooperative Oncology Group

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top